• Pazopanib (GW-786034): ATRX-Aware RTK Assays

  2026-08-15

  Pazopanib (GW-786034) offers a powerful way to study VEGF signaling pathway dependence, angiogenesis inhibition, and genotype-linked drug sensitivity. This guide develops an ATRX-aware assay strategy that separates direct RTK pharmacology from broader tumor growth suppression.

• Cx43/NF-κB Control of AngII-Driven Macrophage Polarization

  2026-08-14

  The reference study shows that angiotensin II drives RAW264.7 macrophages toward an M1-like inflammatory state through a connexin 43–NF-κB signaling axis. By combining molecular profiling with pharmacological inhibition of Cx43 and NF-κB, the work provides a mechanistic framework for studying connexin-dependent inflammation in cardiovascular disease while also defining important limits for translation to other systems.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-14

  The 2021 study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy for suppressing breast cancer growth, stemness, migration, and tumorigenesis. Its mechanistic contribution is the connection of this combination to the c-MYC–G9a–FTH1 axis and HDAC1-associated chromatin regulation, providing a framework for interpreting multi-layer epigenetic and oncogenic dependencies.

• Gramine, CUL3–MTDH, and TNBC Ferroptosis

  2026-08-13

  The reference study identifies Gramine as a candidate ferroptosis inducer that suppresses triple-negative breast cancer through a previously underexplored CUL3–MTDH regulatory axis. By combining target-engagement assays, ferroptosis phenotyping, genetic rescue, and xenograft models, the work connects CUL3-mediated MTDH ubiquitination with therapeutic responses in TNBC research.

• Tacrolimus (FK506) Workflow for Calcineurin Studies

  2026-08-13

  Tacrolimus (FK506) provides a high-potency, mechanism-defined way to interrogate FKBP12–calcineurin control of T-cell activation and cytokine release. This workflow connects careful solvent handling and dose-response design with transplantation immunology research, autoimmune disease models, and translational immune-response studies.

• PD 173074: From MIR9 Biology to Causal Assays

  2026-08-12

  PD 173074 provides a precise pharmacological probe for testing whether MIR9-associated FGFR1 activation is functionally important in acute lymphoblastic leukemia. This article translates the key evidence into a causal assay framework covering pathway validation, controls, dosing logic, and interpretation.

• HotStart 2X Green qPCR Master Mix in Endometriosis

  2026-08-12

  A translational framework for using SYBR Green qPCR to validate the FBLN1–EFEMP1–ferroptosis axis in endometriosis while distinguishing transcript-level evidence from functional mechanism.

• Dual-Network Microgels for Intervertebral Disc Degeneration

  2026-08-11

  The reference study develops an elastic dual-network microsphere that combines sustained miR-155/COS delivery with strontium–EGCG metal-phenolic networks to address inflammation, oxidative stress, and nucleus pulposus cell apoptosis in intervertebral disc degeneration. Its stimulus-responsive design links mechanical stability with oxidative-environment-triggered release, offering a useful framework for integrating biomaterial mechanics and multi-pathway biological regulation.

• Sunitinib Experimental Workflows for Cancer Research

  2026-08-11

  Build reproducible Sunitinib assays that connect RTK inhibition with angiogenesis, apoptosis, cell-cycle control, and treatment resistance. A focused workflow for renal cell carcinoma models also translates TRIB3 knockdown and ferroptosis findings into practical mechanistic experiments.

• Acetylspiramycin (Spiramycin B) Research Guide

  2026-08-10

  Acetylspiramycin, also called Spiramycin B, is a 16-membered macrolide and 50S ribosomal subunit inhibitor for antimicrobial resistance research. Beijing surveillance data show lower acetylspiramycin MICs than erythromycin and azithromycin in macrolide-resistant Mycoplasma pneumoniae isolates, but MIC comparisons do not establish clinical efficacy.

• FGFR1 Regulates Early Human Adipogenesis

  2026-08-09

  Widberg and colleagues showed that FGFR1 activity, rather than mitogenic stimulation alone, controls early adipogenic priming in human preadipocytes. By combining growth-factor comparisons, pharmacological inhibition, signaling assays, and FGFR1 knockdown, the study established a mechanistic link between FGF-1 signaling, preadipocyte proliferation, and later adipocyte differentiation.

• PD 173074: FGFR1 Workflow and Troubleshooting

  2026-08-08

  Learn how to use PD 173074 to interrogate FGFR1 signaling, VEGFR2 inhibition, and angiogenesis-related phenotypes with a reproducible bench workflow. The article also explains why PD 173074 should be used as a mechanistic comparator—not an assumed multidrug-resistance reversal agent—in ABCB1-overexpressing cancer models.

• (R)-MG132 Controls for Proteasome Assays

  2026-08-07

  (R)-MG132 is a functionally inactive MG-132 enantiomer designed to separate genuine proteasome-dependent effects from cytotoxicity, vehicle stress, and off-target biology. Used alongside active MG-132, it strengthens cell-based assay proteasome control and mechanistic interpretation in cancer metabolism studies.

• Sunitinib in Precision Oncology: RTK Inhibition and ATRX-Def

  2026-08-07

  Explore Sunitinib as a multi-targeted receptor tyrosine kinase inhibitor in oncology research. This article delivers a unique, evidence-driven perspective on leveraging Sunitinib for ATRX-deficient tumor models and advanced assay design.

• Fasudil (HA-1077) HCl: Precision ROCK Inhibition in Cancer a

  2026-08-06

  Explore the unique molecular action and advanced research applications of Fasudil (HA-1077) HCl, a selective ROCK inhibitor. Discover how its distinct mechanism supports targeted cell proliferation inhibition and apoptosis induction, setting it apart from conventional pathway modulators.

8364 records 5/558 page Previous Next 12345 下5页 Last page